Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Risk and Volatility
Kiora Pharmaceuticals has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Profitability
This table compares Kiora Pharmaceuticals and Spero Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiora Pharmaceuticals | N/A | -63.38% | -44.33% |
| Spero Therapeutics | 24.90% | 16.17% | 12.57% |
Earnings & Valuation
This table compares Kiora Pharmaceuticals and Spero Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiora Pharmaceuticals | $16.02 million | 0.66 | -$10.84 million | ($2.51) | -0.95 |
| Spero Therapeutics | $42.96 million | 1.63 | $8.57 million | $0.11 | 10.91 |
Spero Therapeutics has higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Kiora Pharmaceuticals and Spero Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiora Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Spero Therapeutics | 0 | 3 | 1 | 0 | 2.25 |
Spero Therapeutics has a consensus price target of $6.00, indicating a potential upside of 400.00%. Given Spero Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Kiora Pharmaceuticals.
Summary
Spero Therapeutics beats Kiora Pharmaceuticals on 13 of the 14 factors compared between the two stocks.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
